Literature DB >> 8698873

Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

W Palinski1, S Hörkkö, E Miller, U P Steinbrecher, H C Powell, L K Curtiss, J L Witztum.   

Abstract

Many reactive products may be formed when LDL undergoes lipid peroxidation, which in turn can react with lipids, apoproteins, and proteins, generating immunogenic neoepitopes. Autoantibodies recognizing model epitopes of oxidized low density lipoprotein, such as malondialdehydelysine, occur in plasma and in atherosclerotic lesions of humans and animals. Because apo E-deficient mice develop particularly high titers of such autoantibodies, we used their spleens to clone 13 monoclonal antibodies to various epitopes of oxidized LDL ("E0 antibodies"). Binding and competitive RIAs demonstrated significant differences in fine specificity even between E0 antibodies initially selected for binding to the same screening antigen. For example, some E0 antibodies selected for binding to malondialdehyde-LDL also recognized copper oxidized LDL, acrolein-LDL, or LDL modified by arachidonic or linoleic acid oxidation products. Circulating IgG and IgM autoantibodies binding to copper-oxidized LDL, 4-hydroxynonenal-LDL, acrolein-LDL, and LDL modified with arachidonic or linoleic acid oxidation products were found in apo E-deficient mice, suggesting that the respective antigens are formed in vivo. Epitopes recognized by some of the E0 monoclonal antibodies were also found on human circulating LDL. Each of the E0 monoclonal antibodies immunostained rabbit and human atherosclerotic lesions, and some of them yielded distinct staining patterns in advanced lesions. Together, this suggests that the natural monoclonal antibodies recognize different epitopes of complex structures formed during oxidation of lipoproteins, or epitopes formed independently at different lesion sites. Our data demonstrate that a profound immunological response to a large number of different epitopes of oxidized lipoproteins occurs in vivo. The availability of "natural" monoclonal autoantibodies should facilitate the identification of specific epitopes inducing this response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698873      PMCID: PMC507491          DOI: 10.1172/JCI118853

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

1.  Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.

Authors:  S Ishibashi; J L Goldstein; M S Brown; J Herz; D K Burns
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.

Authors:  R L Reddick; S H Zhang; N Maeda
Journal:  Arterioscler Thromb       Date:  1994-01

3.  Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk.

Authors:  E Maggi; G Finardi; M Poli; P Bollati; M Filipponi; P L Stefano; G Paolini; A Grossi; P Clot; E Albano
Journal:  Coron Artery Dis       Date:  1993-12       Impact factor: 1.439

4.  A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins.

Authors:  L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

5.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.

Authors:  S D Yan; A M Schmidt; G M Anderson; J Zhang; J Brett; Y S Zou; D Pinsky; D Stern
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

6.  Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein.

Authors:  D W Branch; M D Mitchell; E Miller; W Palinski; J L Witztum
Journal:  Lancet       Date:  1994-03-12       Impact factor: 79.321

7.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.

Authors:  S Ylä-Herttuala; W Palinski; S W Butler; S Picard; D Steinberg; J L Witztum
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47.

Authors:  S G Young; J L Witztum; D C Casal; L K Curtiss; S Bernstein
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

9.  ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum.

Authors:  W Palinski; V A Ord; A S Plump; J L Breslow; D Steinberg; J L Witztum
Journal:  Arterioscler Thromb       Date:  1994-04

10.  A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes.

Authors:  A M Gown; A M Vogel; D Gordon; P L Lu
Journal:  J Cell Biol       Date:  1985-03       Impact factor: 10.539

View more
  170 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Splenic immunity and atherosclerosis: a glimpse into a novel paradigm?

Authors:  Joseph L Witztum
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition.

Authors:  M K Chang; C Bergmark; A Laurila; S Hörkkö; K H Han; P Friedman; E A Dennis; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 4.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

5.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

6.  Lipid peroxidation and Kawasaki disease.

Authors:  F D Faro; J C Burns
Journal:  Pediatr Cardiol       Date:  2003-06-06       Impact factor: 1.655

Review 7.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response.

Authors:  Stanley L Hazen; Guy M Chisolm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

9.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 10.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.